US › Healthcare

ImmunoPrecise Antibodies Ltd. (HYFT)

US · Healthcare · Biotechnology

$1.31-6.43%

Last close · 2026-10-16

Latest quarter · ended 2026-07-31

Revenue

$3.9M

Revenue YoY

+23.2%

Net profit

$-6.2M

EPS

$-0.09

EPS estimate

$-0.05

Net margin

-158.7%

EPS came in at -0.09 against a street estimate of -0.05 — a miss of 80.0%.

Key statistics

Market cap

$64.5M

Forward P/E

0.0

P/B

13.98

Book value

$0.10

EPS (TTM)

$-0.26

52-week high

$2.99

52-week low

$0.99

50-day MA

$1.37

200-day MA

$1.46

Beta

0.78

Analyst view

Analysts rate ImmunoPrecise Antibodies Ltd. a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $4.33.

Shareholding

Insiders

9.14%

Institutions

9.29%

Largest institutional holders

Fund	Stake
Ingalls & Snyder LLC	6.44%
Susquehanna International Group, LLP	1.11%
Renaissance Technologies Corp	0.45%
BlackRock Inc	0.33%
Marshall Wace Asset Management Ltd	0.29%
Bank of Montreal	0.17%
BMO Capital Markets Corp.	0.17%
Allianz Asset Management AG	0.07%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ImmunoPrecise Antibodies Ltd. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.